Human Genome HGSI has received approval from the FDA for its lupus drug Benlysta, which is co-marketed with Glaxoo Smith Kline GSK.
Shares of Human Genome are trading at $25.55, and is still halted.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in